Molecular Marker for Predicting Treatment Response in Advanced Renal Cell Carcinoma: Does the Promise Fulfill Clinical Need?

Current Urology Reports - United States
doi 10.1007/s11934-013-0375-0
Full Text
Abstract

Available in full text

Categories
MedicineUrology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Clinical Experience With Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2015English

Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

Oncology in Clinical Practice
Oncology
2019English

The Tumor Marker for Renal Cell Carcinoma

Japanese Journal of Urology
Urology
1987English

Profile of Temsirolimus in the Treatment of Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

M-Tor Inhibitors in the Treatment of Advanced Renal Cell Carcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2011English

Clinical and Economic Outcomes of Treatment Sequences for Intermediate- To Poor-Risk Advanced Renal Cell Carcinoma

Immunotherapy
OncologyAllergyImmunology
2020English

Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Oncologist
Cancer ResearchMedicineOncology
2015English

Real-World Clinical Outcomes of Pazopanib Immediately Following Immunotherapy Discontinuation for the Treatment of Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2020English

The Bevacizumab Experience in Advanced Renal Cell Carcinoma

OncoTargets and Therapy
OncologyPharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy